380 related articles for article (PubMed ID: 12196291)
1. The interaction properties of costimulatory molecules revisited.
Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
[TBL] [Abstract][Full Text] [Related]
2. Modulation of murine Lyme borreliosis by interruption of the B7/CD28 T-cell costimulatory pathway.
Shanafelt MC; Kang I; Barthold SW; Bockenstedt LK
Infect Immun; 1998 Jan; 66(1):266-71. PubMed ID: 9423867
[TBL] [Abstract][Full Text] [Related]
3. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice.
Sabel MS; Hess SD; Egilmez NK; Conway TF; Chen FA; Bankert RB
Cancer Immunol Immunother; 2005 Oct; 54(10):944-52. PubMed ID: 15846492
[TBL] [Abstract][Full Text] [Related]
5. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes.
Viglietta V; Kent SC; Orban T; Hafler DA
J Clin Invest; 2002 Apr; 109(7):895-903. PubMed ID: 11927616
[TBL] [Abstract][Full Text] [Related]
6. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells.
Eck SC; Turka LA
Cancer Immunol Immunother; 1999 Sep; 48(6):336-41. PubMed ID: 10473809
[TBL] [Abstract][Full Text] [Related]
7. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
Qureshi OS; Zheng Y; Nakamura K; Attridge K; Manzotti C; Schmidt EM; Baker J; Jeffery LE; Kaur S; Briggs Z; Hou TZ; Futter CE; Anderson G; Walker LS; Sansom DM
Science; 2011 Apr; 332(6029):600-3. PubMed ID: 21474713
[TBL] [Abstract][Full Text] [Related]
8. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis.
Reynolds J; Tam FW; Chandraker A; Smith J; Karkar AM; Cross J; Peach R; Sayegh MH; Pusey CD
J Clin Invest; 2000 Mar; 105(5):643-51. PubMed ID: 10712436
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response.
McGaha T; Murphy JW
Infect Immun; 2000 Aug; 68(8):4624-30. PubMed ID: 10899865
[TBL] [Abstract][Full Text] [Related]
10. Modulation of costimulation to enhance tumor immunity.
Vesosky B; Hurwitz AA
Cancer Immunol Immunother; 2003 Nov; 52(11):663-9. PubMed ID: 12920481
[No Abstract] [Full Text] [Related]
11. A mechanistic study of immune system activation by fusion of antigens with the ligand-binding domain of CTLA4.
Chinnasamy D; Tector M; Chinnasamy N; Dennert K; Kozinski KM; Oaks MK
Cancer Immunol Immunother; 2006 Dec; 55(12):1504-14. PubMed ID: 16612600
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapies: the blockade of inhibitory signals.
Wu YL; Liang J; Zhang W; Tanaka Y; Sugiyama H
Int J Biol Sci; 2012; 8(10):1420-30. PubMed ID: 23197939
[TBL] [Abstract][Full Text] [Related]
13. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration.
Wilson CB; Embree LJ; Schowalter D; Albert R; Aruffo A; Hollenbaugh D; Linsley P; Kay MA
J Virol; 1998 Sep; 72(9):7542-50. PubMed ID: 9696851
[TBL] [Abstract][Full Text] [Related]
14. Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
Gong Q; Wang C; Rohr J; Feldman AL; Chan WC; McKeithan TW
Haematologica; 2016 Jun; 101(6):e269-70. PubMed ID: 27252516
[No Abstract] [Full Text] [Related]
15. Differential ligand binding/trafficking for distinct CTLA-4 fates: is it an expandable mechanism?
Kim JE; Kim E; Lee JW
Cell Mol Immunol; 2023 Jan; 20(1):1-2. PubMed ID: 36357521
[No Abstract] [Full Text] [Related]
16. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
van der Merwe PA; Bodian DL; Daenke S; Linsley P; Davis SJ
J Exp Med; 1997 Feb; 185(3):393-403. PubMed ID: 9053440
[TBL] [Abstract][Full Text] [Related]
17. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
18. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Tivol EA; Borriello F; Schweitzer AN; Lynch WP; Bluestone JA; Sharpe AH
Immunity; 1995 Nov; 3(5):541-7. PubMed ID: 7584144
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 control over Foxp3+ regulatory T cell function.
Wing K; Onishi Y; Prieto-Martin P; Yamaguchi T; Miyara M; Fehervari Z; Nomura T; Sakaguchi S
Science; 2008 Oct; 322(5899):271-5. PubMed ID: 18845758
[TBL] [Abstract][Full Text] [Related]
20. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel MF; Allison JP
J Exp Med; 1995 Aug; 182(2):459-65. PubMed ID: 7543139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
